Admin_Adham
New Indication Approved for Juvéderm
The Food and Drug Administration has approved the hyaluronic acid dermal filler Juvéderm Voluma XC for injection in the temple region to improve moderate to severe temple hallowing in individuals over the age of 21.
According to a March 5, 2024, press release from Allergan Aesthetics, an AbbVie company, the development is based on results from a clinical study, which found that more than 80% of adults experienced at least a one-point improvement in moderate to severe temple hollowing 3 months after treatment. This improvement lasted for more than 1 year in 73% of study participants. Also, more than 85% of adults were satisfied with how their face looked 3 months after treatment in terms of balance, proportion, and symmetry, according to the release.
The press release cites a separate randomized, controlled multicenter study of 112 adults, 59% of whom used electronic diaries to record signs and symptoms of treatment site response (TSR). More than half (59%) of these study participants reported experiencing at least one TSR and 70.5% of patients rated the TSRs as mild or moderate (26.3%) in severity. More than half (60%) reported that their TSRs resolved within 3 days.
Juvéderm Voluma XC is also indicated for deep injection for cheek augmentation to correct age-related volume loss in the mid-face, and for augmentation of the chin region to improve the chin profile.
